This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
containing a 20:1 ratio of cannabidiol to delta-9-tretrahydrocanabidiol, with an estimated concentration of 16.0−24.0 mg/mL
Elliott J, et al. Economic Evaluation of Cannabinoid Oil for Dravet Syndrome: A Cost-Utility Analysis. PharmacoEconomics : 14 May 2020. Available from: URL: https://doi.org/10.1007/s40273-020-00923-5
About this article
Cite this article
Cannabinoid oil cost-effective choice for Dravet syndrome in Canada. PharmacoEcon Outcomes News 854, 9 (2020). https://doi.org/10.1007/s40274-020-6839-9